Joseph Sullivan

Long‐term safety and effectiveness of fenfluramine in children and adults with Dravet syndrome

Magnetic resonance imaging findings in <i>SCN1A</i> ‐related epilepsies and Dravet syndrome: A systematic review

Methodology for the Pediatric Dose Optimization for Seizures in Emergency Medical Services (PediDOSE) study

A systematic literature review on the global epidemiology of Dravet syndrome and Lennox–Gastaut syndrome: Prevalence, incidence, diagnosis, and mortality

A comprehensive systematic literature review of the burden of illness of Lennox–Gastaut syndrome on patients, caregivers, and society

Adaptive functioning and neurodevelopment in patients with Dravet syndrome: 12-month interim analysis of the BUTTERFLY observational study

Pediatric Palliative Epilepsy Surgery: A Report From the Pediatric Epilepsy Research Consortium (PERC) Surgery Database

Fenfluramine in the treatment of Dravet syndrome: Results of a third randomized, placebo‐controlled clinical trial

Responsive Neurostimulation in Drug-Resistant Pediatric Epilepsy: Findings From the Epilepsy Surgery Subgroup of the Pediatric Epilepsy Research Consortium

Severe communication delays are independent of seizure burden and persist despite contemporary treatments in <i>SCN1A</i>+ Dravet syndrome: Insights from the <scp>ENVISION</scp> natural history study

A multi‐center comparison of surgical techniques for corpus Callosotomy in pediatric drug‐resistant epilepsy

International consensus on diagnosis and management of Dravet syndrome

Efficacy and Safety of Fenfluramine for the Treatment of Seizures Associated With Lennox-Gastaut Syndrome

The clinical, economic, and humanistic burden of Dravet syndrome – A systematic literature review

Fenfluramine provides clinically meaningful reduction in frequency of drop seizures in patients with Lennox–Gastaut syndrome: Interim analysis of an open‐label extension study

Fenfluramine treatment is associated with improvement in everyday executive function in preschool-aged children (&lt;5 years) with Dravet syndrome: A critical period for early neurodevelopment

Improved everyday executive functioning following profound reduction in seizure frequency with fenfluramine: Analysis from a phase 3 long-term extension study in children/young adults with Dravet syndrome

DRAVET ENGAGE. Parent caregivers of children with Dravet syndrome: Perspectives, needs, and opportunities for clinical research

Fenfluramine significantly reduces day‐to‐day seizure burden by increasing number of seizure‐free days and time between seizures in patients with Dravet syndrome: A time‐to‐event analysis

Surgical evaluation in children &lt;3 years of age with drug‐resistant epilepsy: Patient characteristics, diagnostic utilization, and potential for treatment delays

Fenfluramine HCl (Fintepla^®) provides long‐term clinically meaningful reduction in seizure frequency: Analysis of an ongoing open‐label extension study

Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: a randomised, double-blind, placebo-controlled trial

Possible precision medicine implications from genetic testing using combined detection of sequence and intragenic copy number variants in a large cohort with childhood epilepsy

Immediate outcomes in early life epilepsy: A contemporary account

Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial

<i><scp>PCDH</scp>19</i>‐related epilepsy is associated with a broad neurodevelopmental spectrum

Responsive neurostimulation for treatment of pediatric drug-resistant epilepsy

Why West? Comparisons of clinical, genetic and molecular features of infants with and without spasms

Optimizing the Diagnosis and Management of Dravet Syndrome: Recommendations From a North American Consensus Panel

Early-Life Epilepsies and the Emerging Role of Genetic Testing

Collaborative Research: RUI: Testing Mutualism Theory using Endophytic Fungi and Their Host Grass